Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Evotec AG : Notification and public disclosure of transactions by persons

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/18/2017 | 02:15pm CEST


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

18.09.2017 / 14:12
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Werner
Last name(s): Lanthaler

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Evotec AG

b) LEI
529900F9KI6OYITO9B12 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0005664809

b) Nature of the transaction
Purchase of shares by exercising stock options
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
17.7711 EUR 1064577.75 EUR

d) Aggregated information
Price Aggregated volume
17.7711 EUR 1064577.75 EUR

e) Date of the transaction
2017-09-15; UTC+2

f) Place of the transaction
Outside a trading venue



18.09.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Internet: www.evotec.com

 
End of News DGAP News Service

37751  18.09.2017 


© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/10 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/10 EVOTEC : Achieves first milestone in neurodegeneration alliance with celgene
10/02 EVOTEC : invests in Exscientia to advance AI-driven drug discovery
09/29 EVOTEC AG : Release according to Article 26a of the WpHG [the German Securities ..
09/28 EVOTEC : Invests in Exscientia to Advance AI-Driven Drug Discovery
09/28 EVOTEC : Invests in exscientia to advance ai-driven drug discovery
09/21 EVOTEC : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
09/18 EVOTEC AG : Notification and public disclosure of transactions by persons
More news
News from SeekingAlpha
10/20 Evotec short pitch at Robin Hood conference; shares fall 4%
09/28 Evotec invests in Exscientia to advance AI-driven drug discovery
08/10 Evotec's (EVOTF) CEO Werner Lanthaler on Q2 2017 Results - Earnings Call Tran..
08/10 Evotec AG 2017 Q2 - Results - Earnings Call Slides
08/10 Evotec AG reports Q2 results
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
P/E ratio 2017 104,25
P/E ratio 2018 72,17
EV / Sales 2017 12,0x
EV / Sales 2018 8,87x
Capitalization 2 768 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,2 €
Spread / Average Target -30%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG192.93%3 261
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC33.89%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.208.84%10 522